Fampridine, a medication that improves walking ability in multiple sclerosis patients, has become available on the NHS in England, potentially helping up to 5,000 people.

The drug works by enhancing nerve signal transmission, allowing electrical impulses to travel more effectively across damaged nerve fibers. This mechanism addresses a core problem in MS: the disease damages myelin, the protective coating around nerve cells that enables proper communication. By boosting these weakened signals, fampridine helps restore motor function that MS typically compromises.

Clinical evidence supports the treatment's impact. Studies show that eligible patients experience measurable improvements in walking speed and mobility. The drug requires specific criteria for use. Patients must have confirmed MS diagnosis, demonstrate significant walking limitations, and meet other clinical benchmarks that doctors assess individually.

The NHS approval follows years of fampridine use in other countries. Healthcare systems in the United States and parts of Europe have offered the medication for longer, providing real-world data on safety and effectiveness. This evidence informed England's decision to fund the treatment.

Access depends on specialist assessment. Neurologists evaluate whether patients meet eligibility requirements and can safely tolerate the medication. The approval represents a shift in MS treatment philosophy, moving beyond disease-modifying therapies toward addressing specific functional disabilities that impact daily life.

MS affects approximately 130,000 people in the UK. Many experience progressive walking difficulties that substantially limit independence and quality of life. For those who qualify, fampridine offers a concrete option to regain mobility.

Healthcare professionals emphasize that fampridine works best as part of comprehensive MS care. Physical therapy, disease-modifying treatments, and other rehabilitation strategies remain important components of management. The drug fills a gap in available options by directly targeting the walking disability that concerns many patients most.

Patients interested in fampridine should discuss eligibility with their MS specialist, who can